Z-360 (Nastorazepide) is a novel potent, orally active CCK-2/gastrin receptor antagonist with Ki of 0.47 nM.
Z-360 significantly reduces gastrin-induced PKB/Akt phosphorylation in human CCK-2 receptor-expressing cells.
Z-360 significantly inhibits the growth of MiaPaCa2, also suppresses pancreatic tumor growth and prolong survival in a pancreatic carcinoma xenograft model combined with gemcitabine.
Z-360 prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice.
